ArticleJournal of occupational rehabilitation2026
Changes in Pregabalin Dispensing to Australians with Workers' Compensation Claims for Low Back Pain Following the Listing of Pregabalin on the Pharmaceutical Benefits Scheme.
Article in Journal of occupational rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesWe sought to identify whether the inclusion of pregabalin on the list of medicines subsidised by the Australian government in 2013 resulted in changes to the dispensing of pregabalin to Australians with workers' compensation claims for low back pain.
methodsUsing a sample of workers' compensation claims and payments data (2010-2018), we measured the prevalence of pregabalin dispensing and time to first pregabalin dispensing in workers whose claim began before, during or after pregabalin was listed on the Pharmaceutical Benefits Scheme (PBS) with binary logistic and Cox proportional hazards models. We used interrupted time-series analyses to measure changes in the monthly number, percentage of pain medicines, percentage of gabapentinoid dispensings, and median cost per dispensing of pregabalin.
resultsOf the 17,689 workers included in the study, 13.7% (n = 2431) were dispensed pregabalin during the study period. Workers in the groups whose claim occurred before or during when pregabalin was listed on the PBS were at significantly lower odds of being dispensed pregabalin than the group whose claim began after PBS listing (OR 0.20, 99% CI 0.15, 0.25 and OR 0.40, 99% CI 0.33, 0.48, respectively). There were significant step increases in the number of pregabalin dispensings (26.3%, 99% CI 6.2%, 50.3%), percentage of pain medicines that were pregabalin (29.3%, 99% CI 1.5%, 64.9%), and percentage of gabapentinoid dispensings that were pregabalin (13.9%, 99% CI 7.5%, 20.6%). There was a significant step decrease in the median cost per pregabalin dispensing (- 61.8%, 99% CI - 66.8%, - 56.1%).
conclusionListing pregabalin on the PBS saw significant increases in the prevalence, number and percentage of pain medicines, and significant decreases in time to first pregabalin dispensing and cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.